The antibody-mediated rejection industry is witnessing accelerated business growth driven by advances in targeted therapies and growing transplant volumes. Recent market research highlights evolving market dynamics, with specialized biologics and diagnostic assays reshaping treatment protocols. Industry players are leveraging robust market insights and strategic innovations to address emerging market challenges and expand market scope across regions.

This expert-level overview delves into critical Antibody-mediated Rejection Market size, market share, and market opportunities without rehashing basic definitions, catering to seasoned stakeholders seeking actionable market analysis.



Market size and Overview

The antibody-mediated rejection market is estimated to be valued at USD 142.7 Mn in 2025 and is expected to reach USD 331.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 12.8% from 2025 to 2032.

Fueled by rising transplant rates and expanded use of complement inhibitors, the Antibody-mediated Rejection Market forecast underscores substantial market revenue uptick. Strong investments in next-generation therapeutics and enhanced reimbursement frameworks are key market drivers, while manufacturing complexity and high therapy costs remain market restraints. This Antibody-mediated Rejection Market report offers in-depth market insights and identifies evolving industry trends and market growth strategies.



Key Takeaways:

- Dominating Region: North America continues to lead, with over 45% of global transplant centers in the U.S. reporting antibody-mediated rejection cases in 2024, reflecting robust market share and advanced clinical infrastructure.

- Fastest Growing Region: Asia Pacific is on track with a 15% CAGR from 2025, driven by expanded transplant programs in India and China, highlighting new market opportunities.

- Indication Type Segment:

• Dominant Sub-Segment – Acute AMR, evidenced by 2024 ISHLT data showing a 20% incidence in heart transplant recipients.

• Fastest-Growing Sub-Segment – Chronic AMR, propelled by Hansa Biopharma's imlifidase uptake in the EU transplant cohort.

- Treatment Type Segment:

• Dominant Sub-Segment – Intravenous immunoglobulin (IVIG), with CSL Behring reporting a 10% shipment increase in early 2025.

• Fastest-Growing Sub-Segment – Complement inhibitors, exemplified by Pfizer's eculizumab analogue gaining approval in Japan in 2024.

- End-User Segment:

• Dominant Sub-Segment – Hospitals, accounting for majority of therapeutic administrations in 2024.

• Fastest-Growing Sub-Segment – Specialized transplant centers, expanding by 12% in Latin America.



Market Key Trends

The rapid adoption of targeted complement inhibition represents the most influential trend shaping the Antibody-mediated Rejection Market trends. In 2024, regulatory approval of imlifidase by Hansa Biopharma for desensitization protocols in renal transplantation marked a pivotal shift, with initial quarterly sales surpassing USD 5 Mn. Complement inhibitors demonstrated a 35% revenue growth in North America in 2025, outpacing traditional immunosuppressants.

Driven by improved safety profiles and reduced graft loss, clinical guidelines are increasingly recommending C1s-targeting therapies, as seen in Viela Bio's Phase III trial expansion across European centers. This trend underscores ongoing market growth strategies focused on biologic innovation, addresses market challenges of antibody rebound, and offers compelling market opportunities for pipeline assets. Consequently, market dynamics are favoring companies that invest in high-specificity monoclonal antibodies, signaling a sustained shift in treatment paradigms and enhanced market forecast reliability through 2032.



Key Players

Key market players include: CSL Behring; Hansa Biopharma AB; Viela Bio; Janssen Biotech; Pfizer; Alexion (AstraZeneca); Sanofi Genzyme; Takeda; Grifols; Biotest; Octapharma; Kiniksa Pharmaceuticals; Biogen; Roche; Novartis; Merck; Baxter International; and Fresenius Kabi.


Key players are pursuing collaborative alliances and capacity expansions:

- Hansa Biopharma partnered with leading Nordic transplant centers in 2024, increasing imlifidase enrollments by 25%.

- CSL Behring expanded its IVIG production line in Germany in 2025, boosting quarterly output by 15%.

- Pfizer announced a strategic partnership with a Japanese biotech in 2024 to co-develop next-gen C5 inhibitors, projected to generate USD 30 Mn in first-year sales.



FAQs

1. Who are the dominant players in the Antibody-mediated Rejection Market?

Key players include CSL Behring, Hansa Biopharma AB, Viela Bio, Janssen Biotech, and Pfizer, each leading development in biologics and complement inhibitors.



2. What will be the size of the Antibody-mediated Rejection Market in the coming years?

The market is expected to grow from USD 142.7 Mn in 2025 to USD 331.6 Mn by 2032 at a CAGR of 12%.



3. Which end-user segment has the largest growth opportunity?

Specialized transplant centers show the fastest growth, expanding by 12% in Latin America and adopting advanced treatment protocols.



4. How will market development trends evolve over the next five years?

Continued innovation in complement inhibitors and desensitization drugs will drive market dynamics, with biologic therapies accounting for over 60% of market revenue by 2030.



5. What is the nature of the competitive landscape and challenges in the Antibody-mediated Rejection Market?

The landscape is fragmented with intense R&D competition. Challenges include high therapy costs, manufacturing complexities, and regulatory hurdles in emerging regions.



6. What go-to-market strategies are commonly adopted in the Antibody-mediated Rejection Market?

Strategies include strategic partnerships with transplant networks, expansion of manufacturing capacity, targeted clinical trial collaborations, and region-specific pricing models to address market access.

‣ Get this Report in Japanese Language: 抗体介在性拒絶反応市場

‣ Get this Report in Korean Language:   항체매개거부시장

 ‣ Read More Related Articles :  Sodium Channel Blockers: An Effective Treatment for Several Medical Conditions

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )